Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression

• Published in: The aging male 2017-09, Vol.20 (3), p.175-183
• Main Authors: Akbay, Erdem, Bozlu, Murat, Çayan, Selahittin, Kara, Pelin Özcan, Tek, Mesut, Aytekin, Cuma
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; Androgen deprivation therapy; Androgens; Antigens; Bone Neoplasms - blood; Bone Neoplasms - pathology; Bone Neoplasms - secondary; Case-Control Studies; Disease Progression; Humans; Male; Mens health; Middle Aged; nadir prostate-specific antigen; Older people; Prostate cancer; prostate-specific antigen; Prostate-Specific Antigen - blood; Prostate-Specific Antigen - drug effects; prostate-specific antigen decline slope; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; time to prostate-specific antigen nadir
• ISSN: 1368-5538; 1473-0790
• DOI: 10.1080/13685538.2017.1328675

Introduction: The aim of this study is to evaluate prostate-specific antigen decline pattern including prostate-specific antigen kinetics following androgen deprivation therapy on prostate-specific antigen progression in the patients with advanced prostate cancer. Materials and methods: Ninety-seven advanced prostate cancer patients receiving maximum androgen deprivation therapy were enrolled in case-control study. Baseline prostate-specific antigen, Gleason Score, bone metastase, nadir prostate-specific antigen, time to nadir prostate-specific antigen, declining slope to nadir prostate-specific antigen, estimated baseline prostate-specific antigen half-time, current prostate-specific antigen, post-nadir prostate-specific antigen time, estimated prostate-specific antigen, estimated decline of baseline prostate-specific antigen as quantitative, and ratio were recorded and calculated. Results: The ratio of prostate-specific antigen progression was significantly lower at the patients who had slower declining slope to prostate-specific antigen, longer time to nadir prostate-specific antigen, and lower estimated decline ratio of baseline prostate-specific antigen (p: .016, p: .020, and p: .026, respectively). Conclusions: The shorter time to nadir prostate-specific antigen following androgen deprivation therapy, faster declining slope to nadir prostate-specific antigen and higher estimated decline ratio of baseline prostate-specific antigen are associated with higher risk of disease progression in patients with hormone-sensitive prostate cancer.